Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic

Abstract

Pharmacogenetic (PGx) testing is a tool to identify patients at a higher risk of adverse events or treatment failure. The concern for unwanted side effects can limit medication adherence, particularly in children and adolescents. We conducted a pragmatic study to evaluate the acceptability and feasibility and gather pilot data on the utility of PGx testing in a child and adolescent psychiatry clinic. Both physicians and families participated in the study and answered pre‐survey and post‐survey questionnaires to examine their attitudes toward PGx testing. Patients were randomized into implementation ( N = 25) and control groups ( N = 24) and underwent PGx testing at the beginning or end of the study, respectively. Clinical consult notes with genotype‐guided recommendations were provided to physicians for their consideration in clinical decisions. Patient‐reported symptom severity and antidepressant‐related side effects were assessed at baseline and for 12 weeks. Both participating physicians and families agreed that PGx testing is a useful tool to improve medication selection. The time from sample collection to having PGx test results was ~ 10 days and 15 days to having consult notes available, which may have impaired test utility in clinical decision making. There were no differences in any clinical end point between the implementation and control arms; however, there were higher antidepressant side effect scores for CYP2D6 poor and intermediate metabolizers after the eighth week of treatment. Our findings revealed benefits and pitfalls with the use of PGx testing in the real‐world clinical setting, which may inform the methodology of a larger trial focused on outcomes.

Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications

“…Despite our increasing understanding of depression pathophysiology, clinicians are unable to use biomarkers in blood or cerebrospinal fluid, neuroimaging or genomics to diagnose and guide treatment for MDD 203 . Recent studies suggest that blood levels of sertraline, a common first-line antidepressant, can successfully be predicted through analysis of genes involved in sertraline metabolism and thus, giving an indication of drug effectiveness 204 - 206 . Similarly, blood testing has identified genes (e.g., NRG1 which is involved in regulation of proliferation, survival, and differentiation of many cell types including neurons and epithelial cells 207 ), proteins (e.g.…”

Newer Modalities in Psychopharmacology in Children and Adolescents: A Selective Narrative Review of the Literature

“…In a recent study 57 assessing the acceptability, feasibility, and utility of integrating pharmacogenetic testing in a child psychiatry clinic, Claudio-Campos et al found that pharmacogenomic testing was feasible and well accepted by both providers and families of children with depression and anxiety. Initial concerns from families centered on the social and ethical implications of genetic testing.…”

Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid

“…3 Tertiary pediatric institutions that use pharmacogenetic testing routinely have published on their experiences, which vary from automated testing of specific gene-drug pairs for all pediatric inpatients to specific units or specific testing of patients with specific diagnoses. [4][5][6][7][8][9][10][11][12][13][14][15] Despite the increasing evidence of the association of pharmacogenetic testing with benefits among pediatric patients, common implementation barriers include cost, local testing availability, and testing platform selection. 3 The decision to invest in pharmacogenetic testing implementation could be guided by better data on which drugs with the highest level of evidence for pharmacogenetic-guided dosing are most frequently prescribed or dispensed, the most frequently implicated genes that are known to influence medication dosing, and in which subpopulations these drugs are prescribed.…”